An approach to assess quality of life through biometric monitoring in cancer patients by Silva, Eliana et al.
Metadata of the chapter that will be visualized in
SpringerLink
Book Title New Knowledge in Information Systems and Technologies
Series Title
Chapter Title An Approach to Assess Quality of Life Through Biometric Monitoring in Cancer Patients
Copyright Year 2020
Copyright HolderName Springer Nature Switzerland AG







Organization Centro ALGORITMI – University of Minho
Address Guimarães, Portugal
Email eliana.marisa@hotmail.com







Organization Centro ALGORITMI – University of Minho
Address Guimarães, Portugal
Email







Organization Artificial Intelligence and Computer Science Laboratory (LIACC)
Address Porto, Portugal
Division School of Health
Organization Polytechnic Institute of Porto
Address Porto, Portugal
Email
Author Family Name Faria
Particle





Organization Artificial Intelligence and Computer Science Laboratory (LIACC)
Address Porto, Portugal
Division School of Health
Organization Polytechnic Institute of Porto
Address Porto, Portugal
Email
Author Family Name Reis
Particle





Organization Artificial Intelligence and Computer Science Laboratory (LIACC)
Address Porto, Portugal
Division DEI - FEUP - Department of Informatics Engineering
Organization Faculty of Engineering of the University of Porto
Address Porto, Portugal
Email







Organization LITEC – Innovation and Knowledge Engineering Lab
Address Porto, Portugal
Email







Organization LITEC – Innovation and Knowledge Engineering Lab
Address Porto, Portugal
Division
Organization EST/IPCA – Technology School of Polytechnic Institute of Cávado and Ave
Address Barcelos, Portugal
Email







Organization Centro ALGORITMI – University of Minho
Address Guimarães, Portugal
Email
Abstract Cancer is a serious disease that causes significant disability and suffering, so naturally Health Related
Quality of Life (HRQoL) is a major concern of patients, families and clinicians. This paper intends to
relate biometric indices, in terms of HRV metrics, with self-perceived HRQoL from patients with
lymphoma. Patients (N = 12) answered FACT questionnaire and used a smartband that collected
biometrical data in real-time along the chemotherapy treatment. Our results revealed that Physical Well-
Being, Total, Lymphoma subscale and FACT-Lym Trial Outcome domains seem to have a similar pattern
that HRV metrics across the treatment cycles. In specific, the FACT domains and the HRV metrics have
the lowest average levels on the first cycle and seem to increase along the following cycles (3rd and 6th
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Abstract. Cancer is a serious disease that causes significant disability and
suffering, so naturally Health Related Quality of Life (HRQoL) is a major
concern of patients, families and clinicians. This paper intends to relate bio-
metric indices, in terms of HRV metrics, with self-perceived HRQoL from
patients with lymphoma. Patients (N = 12) answered FACT questionnaire and
used a smartband that collected biometrical data in real-time along the
chemotherapy treatment. Our results revealed that Physical Well-Being, Total,
Lymphoma subscale and FACT-Lym Trial Outcome domains seem to have a
similar pattern that HRV metrics across the treatment cycles. In specific, the
FACT domains and the HRV metrics have the lowest average levels on the first
cycle and seem to increase along the following cycles (3rd and 6th cycles). This
approach of continuous assessment of HRQoL will enable a better accuracy and
more supported clinical decision.
Keywords: Health-related quality of life  Haemato-oncological diseases 
Self-reported measures  Physiological data  Wearable technology 
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1 Introduction
Cancer is a generic term for a large group of diseases that is characterized by an
uncontrolled and abnormal growth of cells [1]. It can affect almost any part of the body
and has many anatomic and molecular subtypes each requiring specific management
strategies.
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People living with cancer can experience significant disability and suffering, so
naturally Quality of Life (QoL) is a major concern of patients, families and clinicians
[2]. Moreover, due to factors such as population ageing, it is estimated that by 2030 it
will be registered in Portugal 60.000 new cases of cancer per year. In fact, cancer is the
second cause of death in this country [3]. Being one of the European countries with the
greatest population ageing, according to the United Nations report [4], Portugal has
more than one million people over 75 years old. Beyond prolonging life, it is essential
also increase patient’s QoL. In particular, the treatment of haemato-oncological dis-
eases, such as lymphoma, often implies high-dose chemotherapy, which can be asso-
ciated with severe symptoms and psychological distress creating difficulties in fulfilling
family and social roles (e.g. be able to work or participating in daily social activities)
and having a major impact in patient QoL [5]. Despite there is no consensus in the
literature, QoL term is seen as a multidimensional (physical, psychological, social, and
spiritual), subjective, and dynamic concept [1]. In other words, QoL is a broad concept
that encompasses all aspects of human life. For that reason, a distinction regarding
focus health-related quality of life (HRQoL) was introduced. This could be defined as
self-perceived aspects of well-being that are related to or affected by the presence of a
disease or treatment [6]. Therefore, HRQoL provides a more holistic evaluation and
positive concept of health, which includes an individual’s experiences, beliefs,
expectations, and perceptions [7]. Being a subjective concept modulated by cultural
and care patterns, the most used way to assess HRQoL is through self-perception
questionnaires [2]. However, there is also an objective component of HRQoL [7],
related to clinical indicators that evaluate symptoms and individual ability to do daily
activities. Because of this multidimensional conceptualization, an appropriate and
effective assessment of HRQoL should incorporate both objective functioning and
subjective well-being.
Recent technological advances in wearable devices have created new opportunities
to collect continuous in real-time, objective patient data in a non-obtrusive manner [8].
Actually, wearable biometric monitoring devices (BMDs) can be an important tool in
the continuous monitoring of biometric data, which can be used to assess patient’s
health status, disease progression and treatment effects [9].
BMDs can be defined as a “biosensor that collects a biological recognition element
(such as blood glucose or sodium levels), anatomical structure (such as tumor size,
infarct size or hippocampal volume) or integrated physiological parameter (such as
heart rate, blood pressure, electroencephalography, mobility, speech and sleep patterns
or speed of information processing)” [9]. In particular, Heart Rate Variability
(HRV) has been widely used as a diagnostic and prognostic tool [11]. In this paper, we
focus on HRV time-domain indices, which quantify the amount of HRV, observed
during monitoring periods [10].
Therefore, the purpose of this study was to evaluate HRQoL in lymphoma patients
throughout chemotherapy treatment and relate its domains to the most common HRV
time-domain metrics assessed in real-time by mobile devices – QLife+ solution.










2 State of the Art
2.1 Health Related Quality of Life in Cancer Patients
HRQoL is considered as a powerful predictor of mortality and morbidity. Specifically,
HRQoL is regarding to both self - reported chronic diseases (e.g. diabetes, arthritis,
hypertension, and cancer) and their risk factors (e.g. body mass index, physical inac-
tivity, and smoking status). So, HRQoL assessment can provide insights into the
relationships between HRQoL and risk factors as well as determine the burden of
preventable disease, injuries and disabilities. Moreover, HRQoL is now considered an
important aspect in clinical practice for patients with chronic illnesses [12].
One of the most used questionnaires to evaluate HRQoL in cancer patients is the
Functional Assessment of Chronic Illness Therapy (FACT) focusing on the previous 7
days. It includes a combination of inputs from experts and patients ensuring the
inclusion of clinically important issues that are also relevant to the patient [13]. It has a
general core (FACT-G), which is common for all patients with cancer, it is composed
by 27 general items divided into four domains, namely Physical well-being (PWB; 7-
items), Social/Family well-being (SWB; 7-items), Emotional well-being (EWB; 6-
items), and Functional well-being (FWB; 7-items). Adding to this general core, there
are several extensions specific to other chronical illness conditions such as lymphoma
(FACT-Lym; 15 items) [13]. In particular, the Trial Outcome Index score have been
reported as an efficient summary index of physical/functional outcomes and it is very
responsive to change of the patient [13]. “While social and emotional well-being are
very important to HRQoL, they are not as likely to change as quickly or dramatically
over time or in response to physical health interventions” such as chemotherapy [13].
All items are evaluated in a 5-point Likert scale (from 0 to 4).
It is important to notice that assessing HRQoL throughout questionnaires face some
challenges such as: time constraints and frequency overload, the response and recall
bias where the patient may not have a complete recollection of their feelings and
symptoms and by the desire to enroll in a trial or receive therapy resulting in the over
reporting of their health status [8]. Other important challenge associated to question-
naires is “the static nature of the assessment only captured periodically, and the
patient’s health status is dynamic over the course of the treatment and can change on a
daily basis” [8]. Therefore, it is important to complement the questionnaire information
with biometric data in an objective and non-invasive manner.
2.2 Biometrics Data – Heart Rate Variability
The autonomic nervous system (ANS), composed by the sympathetic and parasym-
pathetic branches, acts as a control system of blood vessels, glands and muscles,
including the heart [14]. The continuous non-linear modulation of the ANS, results in
complex and non-linear variations in HRV [10, 15]. “HRV is an emergent property of
interdependent regulatory systems which operate on different time scales so that the
patient has the flexibility to adapt to the environmental and psychological challenges”










[10]. It has been recognized to be a useful non-invasive tool to predict several
pathologies such as myocardial infarction, diabetic neuropathy, sudden cardiac death
and ischemia, among others [16].
Typically, statistical variables are calculated over 5 min length ECGs segments)
[10, 15]. Time-domain indices of HRV quantify the amount of variability in mea-
surements of the interbeat interval, which is the time period between successive
heartbeats [10]. There exist a wide variety of time domain parameters, but we will
focus on one described on Table 1.
The intervals between consecutive heart beats needed to construct the time series




The communication architecture implemented in the collection of biometric parameters
in the QLife+ project, is based on the Microsoft Band 2 device, connected via Blue-
tooth protocol, to an Android smartphone, which in turn collects data from the wear-
able device’s sensors. In this architecture, there is a set of proprietary and OpenSource
technologies, linked and exchanging data, allow the collection and storage of biometric
data. For attending this purpose, we need database tools, web server, mobile applica-
tion - where these tools have adopted technologies such as PostgreSQL, Microsoft IIS
Web Server - and an Android application. In order to provide communication between
these technologies, different protocols are used, such as HTTPS in the communication
between the mobile application and the web server, and an HTTP in the communication
between the web server and the database PostgreSQL, given in a secure internal
network.
Table 1. Time domain parameters description
Parameters Unit Description
Mean HR bpm Mean heart rate
Mean RR ms Mean RR interval
RMSSD ms Root mean square of successive differences
SDNN ms Standard deviation of the RR interval
SDANN ms Standard deviation of the average RR intervals calculated over short
periods
pNN50 % Proportion of successive RR intervals greater than 50 ms











Participants were recruited from one public Hospital in Portugal. Patient eligibility
criteria included: histological diagnosis of lymphoma, being aged 18 years or older,
confirmed to receive treatment at that Hospital, and considered by the oncologist and the
researchers to be emotionally and physically capable of participating. After oncologist
referral, participants were invited to participate and received an informative flyer. All
participants provided their written informed consent to participate in this study.
Participants were interviewed at baseline (pretreatment or on the day of their first
chemotherapy treatment), at several times during active treatment (first, third, and sixth
chemotherapy cycle), and every three months at the follow-up.
At baseline, participants were asked to answer a brief sociodemographic ques-
tionnaire. They were given brief training on the BMD, specifically a smartband
(Microsoft Band 2), and received written information with general instructions. Par-
ticipants used the smartband during one or two weeks at pretreatment, and during two
consecutive weeks at first, third, and sixth chemotherapy cycle. At the end of each
week, they answered FACT-Lym. For this study, data were collected between February
until October 2018.
3.3 Participants
Forty-seven patients were asked to participate in the study. Of these, 16 patients agreed
to take part in the study. However, 4 participants were not included in the analyses due
to the reduced biometric data. Six participants (50.0%) were female and 6 (50.0%) were
male. Participants averaged 53.17 years old (SD = 16.73, range: 19–71 years). Con-
cerning marital status, five (41.7%) participants were married, three (25.0%) were
single, two (16.7%) were widowed, and two (16.7%) were separated. Four participants
(33.3%) have the 4th grade, two (16.7%) have incomplete or complete 9th grade, four
(33.3%) have incomplete or complete 12th grade, and two (16.7%) have higher
education.
3.4 Questionnaires and Biometric Data Preprocessing
All domains of the FACT were standardized to 0–100 scale. The physiological sensor
in the wearable device is a light source that calculates a RR. The signals were recorded
wirelessly and features were extracted after preprocessing the heart rate series, which
were created with the standard approach: considering only 5 min length.
Artifacts were removed from the signal using a “adaptive threshold for rejecting
value differs from previous and following beats, and from a mobile mean more than a
threshold value and removing points that are not within acceptable physiological
values” [17].
Measurements described on Table 1 were calculated and it was only selected the
ones that matched the dates covered by the questionnaires. All parameters in the
selected range were averaged. Moreover, since the measure are calculated based on
short-term (5-min) variations it may experience some correlation and so it was selected
the HR, RMSSD and the SDNN to analyze.











Considering the FACT scores, patients experienced lower scores on the Functional
Well – Being domain and higher on the Social/Family Domains. Throughout the
cycles, patients experienced a decrease of the Lymphoma Subscale, Physical Well-
Being and Total in the first cycle regaining the QoL in the third and sixth cycles.
FACT-G experienced slight decrease until the third cycle. The Emotional subscale
presented an oscillatory trend and Social/Family decreased on the third cycle. The
average of the HR did not appear to follow similar trend across the cycles as all the
FACT domains scores. It is also important to notice the high variability of the Emo-
tional Well-Being scores in the Third and Sixth cycle and in the Functional domain in
the pre-treatment and first cycles. The Physical Well – Being has higher variability in
the third cycle.
(Figure 2, Table 2).












PreTr 63.7 ±12.43 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 74.1 ±13.28 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 69.7 ±18.86 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 78.4 ±17.85 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
Functional
well-being
PreTr 58.7 ±19.10 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 53.6 ±15.5 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 49.9 ±13.2 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 59.4 ±12.1 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
Lymphoma
subscale
PreTr 74.0 ±8.4 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 68.1 ±11.2 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 74.8 ±16.2 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 81.2 ±12.1 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
Physical well-
being
PreTr 79.1 ±12.9 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 57.6 ±15.0 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 72.9 ±21.1 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 79.9 ±17.0 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
Social/family
well-being
PreTr 79.9 ±19.1 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 82.3 ±15.5 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 74.4 ±15.7 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 73.1 ±13.4 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
FACT-G total
score
PreTr 74.7 ±9.5 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 72.3 ±10.7 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 70.7 ±11.1 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 78.1 ±12.5 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
(continued)










In the Physical Well-Being, Total, Lymphoma subscale and FACT-Lym Trial
Outcome domains, the SDNN parameters followed the similar pattern exhibited by the
domains scores across the cycles (Fig. 3, Table 2). The RMSSD parameter also
exhibited similar pattern as the scores across the cycles in the FACT-Lym Trial Out-
come Index, Lymphoma subscale, Physical Well-Being and Total (Fig. 4, Table 2).














PreTr 71.6 ±9.9 78.6 ±5.0 79.1 ±19.5 81.1 ±19.2
1st 62.1 ±7.8 80.1 ±5.7 78.0 ±14.2 78.6 ±16.1
3rd 68.3 ±14.6 82.5 ±6.0 80.5 ±16.5 82.8 ±20.3
6th 75.6 ±10.7 82.4 ±5.8 83.4 ±21.0 86.4 ±24.5
Total PreTr 71.8 ±10.0 78.6 ±5.0 79.1 ±19 81.1 ±19.2
1st 67.2 ±6.2 80.1 ±5.7 78.0 ±14. 78.6 ±16.1
3rd 69.5 ±11.5 82.5 ±6.0 80.5 ±16 82.8 ±20.3
6th 75.6 ±9.7 82.4 ±5.8 83.4 ±21 86.4 ±24.5
Fig. 1. Mean score of FACT (and standard deviation) and mean of HR (and standard deviation)
per Domain and per cycle of chemotherapy
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Fig. 2. Score of FACT and mean of SDNN per domain and per cycle of chemotherapy
Fig. 3. Score of FACT and mean of RMSSD per domain and per cycle of chemotherapy











The QLife+ Solution is an ongoing research, whose main goal is creating a new
paradigm for the evaluation of HRQoL in clinical practice. The solution devised is
based on an adaptive information system (IS), able to use physical and behavioral data
of the patient, allowing continuous assessment of HRQoL that significantly reduce the
questionnaires response time without affecting the patient’s daily life. Continuous
assessment of HRQoL will enable a better accuracy and more supported clinical
decision [12].
In this paper, we focused to evaluate the existence of a possible relationship
between self-perceived HRQoL domains and physiological data in terms of HRV
metrics. Our results revealed that lymphoma patients experienced variations in HRQoL
score throughout the cycles, being the Functional Well-being the domain with the
lowest scores and the Social/Family with the highest. The first cycle presents as a
particularly difficult moment reflected on the FACT-G, FACT-Lym Trial Outcome
Index, Physical Well-Being, Lymphoma Subscale and Total.
In general, those results are in accordance with previous researches. In fact, it is
common to verify a decline in Functional well-being both in lymphoma patients and
survivors [18] that increases with the existence of additional chronic conditions. In
comparison, Social/Family well-being has the highest values as found in a previous
study [19]. Lymphoma patients commonly report a decrease in Physical Well-Being
and overall HRQoL with treatment, as we have found with the lowest levels of well-
being in the first cycle of chemotherapy. However, these effects may be reversed with
physical activity which is recommended in cancer treatment [18, 20].
HRV seems to provide valuable information in the comprehension of pathological
conditions in order to monitor the individuals’ well-being [21]. In specific, higher HRV
means a good physiological adaptation of the organism whereas lower HRV is a
predictor of diseases or adverse events in patients with already diagnosed diseases [22].
Our results revealed that for Physical Well-Being, Total, Lymphoma subscale and
FACT-Lym Trial Outcome domains, the SDNN and RMSSD parameters revealed a
similar pattern as the domain scores. In specific, the FACT domains and the HRV
metrics have the lowest average levels on the first cycle and seem to increase along the
following cycles (3rd and 6th cycles). These results seem to suggest that individuals are
more severely affected in the first cycle exhibiting lower HRV and lower self-perceived
HRQoL. According to the literature, it is expected to found lower HRV in individuals
during chemotherapy treatment. However, this effects “appeared to be reversible with
treatment cessation” [21], which will be evaluated in our future studies, when the
participants will have completed the follow-up evaluations. In addition, HRV values
depend on the disease stage, being reduced in patients with the more affected disease.
Accordingly, our future studies will integrate the patients’ clinical data (e.g., clinical
stage) to provide a more complete understanding of the HRV and HRQoL according to
the disease. This study extends the current knowledge regarding the HRQoL in lym-
phoma patients by evaluating this construct through self-reported data and biometric
information collected in real-time along the chemotherapy treatment.
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